Key Takeaways
- British Columbia will require anyone receiving prescribed alternatives to illicit drugs to ingest them under the supervision of a health care provider, starting December 30.
- The new policy aims to reduce the likelihood of diversion and trafficking of prescribed alternatives, but has faced criticism from doctors and pharmacists who argue it will restrict access to the program.
- The safer supply program has faced challenges and criticism since its launch in 2020, including limited availability of medications and concerns over diversion and trafficking.
- Despite these challenges, studies have shown that the program has been associated with fewer deaths and improved treatment adherence.
- The BC government has faced pushback from experts and advocates who argue that the program should be expanded to include low-barrier safer supply models and community-based agencies.
Introduction to the New Policy
The British Columbia government is set to announce a new policy that will require anyone receiving prescribed alternatives to illicit drugs to ingest them under the supervision of a health care provider. This policy, which is set to take effect on December 30, is aimed at reducing the likelihood of diversion and trafficking of prescribed alternatives. The new policy builds on interim guidance issued earlier this year, which required witnessed consumption for new patients and directed prescribers to discuss witnessed dosing with existing patients. The change follows considerable scrutiny and political pushback on the safer supply program, which has been criticized for its limited accessibility and concerns over diversion and trafficking.
Challenges and Criticisms of the Safer Supply Program
The safer supply program, which was launched in 2020 in response to the increasingly toxic street drug supply, has faced numerous challenges and criticisms. Despite its goal of providing regulated substances to those at high risk of overdose, the program has been limited by its medicalized approach, which requires patients to have a willing prescriber. This has resulted in limited access to the program, with many patients unable to find a prescriber or facing long wait times. Additionally, the program has been criticized for its limited medication availability, with hydromorphone, the most commonly prescribed opioid, often being too weak to meet the needs of those with high opioid tolerances from fentanyl use. These challenges have led to some users selling or trading their prescribed alternatives for illicit fentanyl, further exacerbating the problem.
Expert Opinions and Concerns
Doctors and pharmacists have expressed frustration and concern over the new policy, arguing that it will further restrict access to the program and limit the ability of healthcare providers to make medical decisions. Ryan Herriot, a family physician and addiction medicine specialist, has stated that the change represents an "egregious interference by non-experts into the practice of medicine." He cites studies that have shown the program to be associated with fewer deaths and improved treatment adherence, and argues that the Ministry of Health does not have the expertise to direct clinical care. Dr. Herriot also notes that the top concern of his patients is staving off withdrawal overnight, when witnessed dosing at a pharmacy is impossible.
Background and Context
The safer supply program was launched in response to the increasingly toxic street drug supply, which has driven one of Canada’s deadliest public health emergencies on record. The program is predicated on the idea that by providing regulated substances of known potencies, healthcare providers can reduce or sever users’ dependence on street drugs, lowering their risk of death and related drug harms. Despite its challenges, the program has been shown to be effective in reducing deaths and improving treatment adherence. However, the program has faced pushback from politicians, including Federal Conservative Leader Pierre Poilievre, who has called the program a "failed taxpayer-funded hard drugs experiment."
Implications and Future Directions
The new policy has significant implications for the safer supply program and its patients. Limited exemptions from witnessed dosing will be available in extraordinary circumstances, but it is unclear how these exemptions will be determined and implemented. The Ministry of Health has stated that the change will preserve the benefits of the program while reducing perceived harms, but experts and advocates argue that the policy will restrict access and limit the ability of healthcare providers to make medical decisions. As the program continues to evolve, it is essential to consider the needs and concerns of patients, healthcare providers, and experts in the field. This includes expanding the program to include low-barrier safer supply models and community-based agencies, as well as increasing medication availability and accessibility. By working together, it is possible to create a more effective and accessible safer supply program that meets the needs of those at high risk of overdose.